Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Inclusion Criteria:

* 1.Histologically confirmed ESCC;
* 2.Clinical stage T1-2N2-3M0 or T3N1-3M0 or T4N0-3M0(AJCC 8 TNM classification);
* 3.Have a performance status of 0 or 1 on the ECOG Performance Scale;
* 4.The important organs functions meet the following requirements:the absolute neutrophil count(ANC) ≥1.5×109/L; the platelet count ≥100×109/L; hemoglobin ≥90g/L; bilirubin is less than or equal to 1.5 times ULN, ALT and AST less than or equal 2.5 times UILN; creatinine clearance rate(CCr) ≥50mL/min; the thyroid function is normal;
* 5.Expected survival time is greater than or equal to 3 months;
* 6.Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;
* 7.Female subjects of childbearing potential must be willing to use an adequate method of contraception - Contraception, for the course of the study through 90 days after the last dose of study medication;
* 8.Be willing and able to provide written informed consent/assent for the trial.

Exclusion Criteria:

* 1.Has any active autoimmune disease or a history of autoimmune disease;
* 2.The patient is receiving systemic steroid therapy or any other form of immunosuppressive therapy;
* 3.The patient had active infection, fever of unknown cause ≥38.5℃ within 7 days before the medication, or white blood cell count at baseline \>15×109/L;
* 4.The patient had previously received other anti-pd-1 antibody therapy or other immunotherapy targeting pd-1 / pd-L1,or received chemoradiotherapy;
* 5.Have a history of mental illness or psychiatric substance abuse;
* 6.Patients who had participated in clinical trials of other drugs within 4 weeks;
* 7.Patients with a serious risk to treating patients' safety or a concomitant disease that affects the completion of the study according to the researchers judgment;
* 8.Senior or uncontrolled virus injection: HIV, TP, hepatitis virus;
* 9.Other patients whom the medical practitioner considers inappropriate for inclusion.